TherapeuticsMD (TXMD) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
TherapeuticsMD Announces Third Quarter 2018 Financial Results
November 7, 2018 4:05 PM EST-Strong early launch indicators for IMVEXXY-
-BIJUVA commercial launch planned for 2Q 2019-
-ANNOVERA commercial launch planned for 4Q 2019-
-Conference call scheduled for 4:30 p.m. ET today-
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative womens healthcare company, today announced its clinical and corporate update for the quarter ended September 30, 2018.
We are extremely pleased with the momentum of the IMVEXXY launch, including our progress with negotiating commercial payer coverage, said Robert G. Finizio, Chief... More
